Cardio3 BioSciences Has Been Selected to Present C3BS-CQR-1 Trial Data in Late Breaking Clinical Trial Session at European Society of Cardiology 2012 Heart Failure Congress
MONT-SAINT-GUIBERT, Belgium, May 18, 2012/PRNewswire/ --The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces that the final results of its Phase II clinical trial of C3BS-CQR-1 is will be presented at the late breaking clinical trial session at the European Society of Cardiology 2012 Heart Failure Congress in Belgrade, Serbia taking place on May 19-22.
Andre Terzic, M.D., Ph.D, Director at Center of Regenerative
Medicine, Mayo Clinic, the co-lead investigator on the trial, will
present new final follow up data on the Company's stem cell therapy
for heart failure, C3BS-CQR-1, which is based on "Cardiopoiesis"
proprietary technology. The presentation will be held on Sunday,
May 20th in Belgrade, Serbia.
Dr. Christian Homsy, CEO of Cardio3 BioSciences, said: "Being
selected to present the final follow-up data in the late breaking
clinical trial session at this prestigious cardiology congress
highlights the quality of our technology and reiterates our belief
in C3BS-CQR-1 as a potential treatment for patients with heart
failure, a condition with a significant unmet medical need. We look
forward to advancing the product into Phase III."
About Cardio3 BioSciences
Cardio3 BioSciences is a Belgian leading biotechnology company
focused on the discovery and development of regenerative and
protective therapies for the treatment of cardiac diseases. The
company was founded in 2007 and is based in the Walloon region of
Belgium. Cardio3 BioSciences leverages research collaborations in
the US and in Europe with Mayo Clinic and the Cardiovascular Center
Aalst, Belgium.
The Company's lead product candidate C3BS-CQR-1 is an innovative
pharmaceutical product consisting of autologous cardiac progenitor
stem cells. C3BS-CQR-1 is based on ground breaking research
conducted at Mayo Clinic that allowed discovery of cardiopoiesis, a
process to mimic in adult stem cells the natural signals triggered
in the early stages of life during the cardiac tissue development.
Cardio3 BioSciences has also developed C-Cath(R), the
next-generation injection catheter with superior efficiency of
delivery of bio therapeutic agents into the myocardium.
C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3
BioSciences and C-Cath logos are trademarks or registered
trademarks of Cardio3 BioSciences SA, in Belgium, other countries,
or both. Mayo Clinic holds equity in Cardio3 BioSciences as a
result of intellectual property licensed to the company. In
addition to historical facts or statements of current condition,
this press release contains forward-looking statements, which
reflect our current expectations and projections about future
events, and involve certain known and unknown risks, uncertainties
and assumptions that could cause actual results or events to differ
materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. These forward-looking statements are
further qualified by important factors, which could cause actual
results to differ materially from those in the forward-looking
statements, including timely submission and approval of anticipated
regulatory filings; the successful initiation and completion of
required Phase III studies; additional clinical results validating
the use of adult autologous stem cells to treat heart failure;
satisfaction of regulatory and other requirements; and actions of
regulatory bodies and other governmental authorities. As a result,
of these factors investors and prospective investors are cautioned
not to rely on any forward-looking statements. We disclaim any
intention or obligation to update or review any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information contact:
Cardio3
BioSciences:
http://www.c3bs.com
Dr Christian Homsy,
CEO
Tel : +32-10-39-41-00
Anne Portzenheim, Communication
Manager aportzenheim@c3bs.com
CitigateDeweRogerson
Tel : +44-(0)-207-638-9571
Chris Gardner/Nina
Enegren
nina.enegren@citigatedr.co.uk
Hill &
Knowlton
Tel : +32-2-737-95-00
Katia
Delvaille
kdelvail@hillandknowlton.com
Source: Cardio3 BioSciences
Posted: May 2012
